Pulmonary Fibrosis News and Research

RSS

Advancing pulmonary fibrosis treatment through targeted drug delivery

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, and leading to impaired lung function and respiratory failure.

14 Apr 2025

This bill aims to help firefighters with cancer. Getting it passed is just the beginning.

As firefighters battled the catastrophic blazes in Los Angeles County in January, California's U.S. senators, Adam Schiff and Alex Padilla, signed onto legislation with a simple aim: Provide federal assistance to first responders diagnosed with service-related cancer.

9 Apr 2025

Pregnancy may provide some protection against Long COVID

Pregnancy may offer some protection from developing Long COVID, found a new study led by Weill Cornell Medicine, University of Rochester Medical Center, University of Utah Health and Louisiana Public Health Institute.

1 Apr 2025

Blocking Piezo2 may offer a new therapeutic approach for pulmonary fibrotic diseases

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical forces in tissues including stress, strain, and stiffness.

25 Mar 2025

Study shows impact of statins and aspirin on muscle health in smokers

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

13 Mar 2025

Insilico Medicine's AI-driven drug Rentosertib receives official generic name

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF) – Rentosertib (formerly known as ISM001-055) – has been granted an official generic name by the United States Adopted Names (USAN) Council.

7 Mar 2025

Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025

The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of Community Health Workers (NACHW) announce their collaboration to address idiopathic pulmonary fibrosis (IPF) as a chronic disease on Rare Disease Day 2025.

28 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

New discovery offers hope in the battle against pulmonary fibrosis

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe.

20 Feb 2025

Insilico Medicine announces preclinical drug discovery benchmarks from 2021 to 2024

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate nominations achieved by its platform from 2021 to 2024.

11 Feb 2025

USF study: Pulmonary fibrosis after COVID-19 tends to get better

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

23 Jan 2025

Women experience higher waiting-list mortality in lung transplantation

Research highlights gender-based disparities in lung transplantation, showing women face longer wait times yet achieve better post-transplant survival outcomes.

13 Jan 2025

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies.

10 Jan 2025

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis.

12 Dec 2024

Study reveals pathways behind organ damage in severe COVID-19

New research published in the journal Proceedings of the National Academy of Sciences sheds light on the pathways that drive organ damage and death in severe COVID-19 and helps explain why survivors of the disease can experience long-term complications.

2 Dec 2024

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

23 Oct 2024

Boston University and GSK collaborate to tackle pulmonary fibrosis

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research focused on developing cutting-edge models to study and treat lung diseases like pulmonary fibrosis.

17 Oct 2024

Anti-fibrotic drug shows promise in breast cancer

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of HER2-negative cancers varies among patients, so one goal is to be able to classify tumors in more detail and thus determine the best treatment for each case.

20 Sep 2024

New study offers hope for extending ovarian healthspan and function

A woman's ovaries are like a factory where eggs grow and produce hormones that regulate everything from menstruation and pregnancy to bone density and mood.

17 Sep 2024